

Product Update

atomoxetine oral solution 4mg/mL (Strattera[®]) SMC No. (1107/15)
Eli Lilly and Company Limited

06 November 2015

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

atomoxetine oral solution (Strattera[®]) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.

SMC restriction: to use in patients who are unable to swallow capsules.

Atomoxetine oral solution demonstrated bioequivalence to atomoxetine capsules. The availability of the oral solution will provide a formulation acceptable to patients who cannot swallow capsules. Any overall budget impact is likely to be small.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 14 September, 2015.

Vice-Chairman
Scottish Medicines Consortium